Watch Our Nursing Home Masterclass
estate planning and elder law

What’s the Latest on Alzheimer’s Therapies?

Elder Scams and POAs: Protecting Yourself from AI-Powered Fraud
The FDA has approved brexpiprazole (Rexulti) opens in a new tab or window for agitation associated with Alzheimer's disease dementia, the agency announced on Thursday.

At Beck, Lenox & Stolzer Estate Planning and Elder Law, we are honored to assist and protect all of our clients, particularly those who have been diagnosed with Alzheimer’s. That’s why learning what’s the latest on Alzheimer’s therapies interested us. The new indication for a drug called brexpiprazole will make it the first FDA-approved treatment for Alzheimer’s. The atypical antipsychotic was previously approved for treating major depressive disorder and schizophrenia, reports MedPage Today’s recent article entitled, “FDA OKs First Drug for Agitation in Alzheimer’s Dementia.”

“Agitation is one of the most common and challenging aspects of care among patients with dementia due to Alzheimer’s disease. ‘Agitation’ can include symptoms ranging from pacing or restlessness to verbal and physical aggression,” said Tiffany Farchione, MD, director of the division of psychiatry in the FDA’s Center for Drug Evaluation and Research, in a press release.

“These symptoms are leading causes of assisted living or nursing home placement and have been associated with accelerated disease progression.”

In April, an advisory committee voted 9-1 in favor of the expanded indication. Advisors noted that the data presented at the meeting were sufficient to identify a population in whom the benefits of treatment outweighed its risks.

Committee members largely agreed that this indication would benefit elderly patients. However, they expressed concerns over the relatively limited safety data for the treatment.

Researchers found that treatment achieved a statistically significant reduction in agitation over a 12-week treatment period, based on the Cohen Mansfield Agitation Inventory (CMAI). Patients on a 2-mg or 3-mg daily dose of brexpiprazole had improved CMAI scores versus placebo.

The trials also showed that the drug had a similar safety profile compared with the treatment’s use in adults with schizophrenia and major depressive disorder.

Brexpiprazole’s label will continue to carry a boxed warning about the risk of increased mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs.

The warning further states that the drug isn’t approved for patients with dementia-related psychosis who aren’t experiencing agitation associated with Alzheimer’s.

The most common side effects of brexpiprazole among patients with agitation associated with dementia due to Alzheimer’s include headache, dizziness, urinary tract infections, nasopharyngitis and trouble with sleep.

While we are hopeful about the latest Alzheimer’s therapy, physicians and researchers will remain vigilant on any contraindications surrounding this treatment. Just as they will, Beck, Lenox & Stolzer carefully explores the needs of our Alzheimer’s clients to insure that the best decisions are made on their behalf. Keep up-to-date on our efforts to assist all clients by visiting our website.

Reference: MedPage Today (May 11, 2023) “FDA OKs First Drug for Agitation in Alzheimer’s Dementia”

Subscribe to Our Free Monthly E-Newsletter & Blog Digest!

Recent Posts

Need to Email Us?

If we are currently working with you or your family member, please DO NOT use this email as it may take longer to route your inquiry to the specific person working on your file. Instead, please call our office at (636) 946-7899 so we may better serve you

For all other inquiries: